Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study of RO7821657 in Participants With Solid Tumors

13 de noviembre de 2026 actualizado por: Hoffmann-La Roche

A First In-Human, Multicenter, Phase I Clinical Study of RO7821657, a Protease Activated TCB Antibody That Targets CEACAM5, in Participants With Locally Advanced and/or Metastatic Solid Tumors

The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s) (RP2D[s])

The study consists of two parts, namely Part 1 and Part 2:

Part 1: Evaluation of RO7821657 as monotherapy in participants with microsatellite-stable (MSS) colorectal cancer (CRC).

Part 2: Evaluation of RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer (NSCLC)

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

405

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • København Ø, Dinamarca, 2100
        • Reclutamiento
        • Rigshospitalet
      • Sutton, Reino Unido, SM2 5PT
        • Reclutamiento
        • Royal Marsden Sutton

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Life expectancy estimated by the Investigator to be ≥12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
  • Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; previously irradiated lesions are considered measurable if progression has been demonstrated in such lesions after the irradiation.
  • Availability of archival tumor tissue or tissue obtained from a fresh biopsy at screening if formalin-fixed paraffin-embedded [FFPE]-preserved archival tissue is not available. The archival tumor tissue should come from a core biopsy, a punch biopsy, an excisional biopsy, or a surgical specimen. Lymph node biopsy, bone biopsy (unless from soft tissue), or fine needle aspiration are unacceptable for submission. Lesions that are intended to be biopsied should not be counted as target lesions.
  • Adequate cardiovascular function:

New York Heart Association (NYHA) Heart Failure Class ≤ 1.

  • Agreement to adhere to the contraception requirements.

Exclusion Criteria:

  • Participants with active Central Nervous System (CNS) metastases.

  • Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted or checkpoint inhibitor therapy or surgical procedure, greater than CTCAE Grade 1 at the time of starting study treatment, except for alopecia and Grade 2 neuropathy.

    a) Stable endocrine AEs managed with hormone replacement are permitted, including hypothyroidism on stable thyroid hormone replacement.

  • History of interstitial pulmonary disease, drug-induced pneumonitis, or evidence of active pneumonitis on screening computed tomography (CT) scan.

  • Participants with pulmonary miliary metastatic pattern (innumerable small lesions) or pulmonary lymphangitic carcinomatosis.

  • Active autoimmune disease that has required systemic treatment (except replacement treatment) within the last 2 years or any disease requiring immunosuppressive therapy while on study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part 1A: Dose Escalation

Participants with MSS CRC will receive multiple doses of RO7821657 in single and multiple participant cohorts.

Participants will receive RO7821657 as per the schedule described in the protocol.

Experimental: Part 1B: Backfill Cohorts

Participants with MSS CRC will receive RO7821657 at dosing regimen selected based on data from Part 1A.

Participants will receive RO7821657 as per the schedule described in the protocol.

Experimental: Part 1C: Dose Expansion/Optimization

Participants with MSS CRC will receive RO7821657 at dosing regimens selected based on data from Parts 1A and 1B.

Participants will receive RO7821657 as per the schedule described in the protocol.

Experimental: Part 2A: Abbreviated Dose Escalation

Participants with non-squamous NSCLC will receive multiple doses of RO7821657 in multiple participant cohorts.

Participants will receive RO7821657 as per the schedule described in the protocol.

Experimental: Part 2B: Dose Expansion/Optimization

Participants with non-squamous NSCLC will receive RO7821657 at dosing regimen selected based on data from Part 2A.

Participants will receive RO7821657 as per the schedule described in the protocol.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Part 1: Incidence and Severity of Adverse Events (AEs)
Periodo de tiempo: Up to approximately 27 months

AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria

Up to approximately 27 months
Part 2: Incidence and Severity of Adverse Events (AEs)
Periodo de tiempo: Up to approximately 27 months

AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria

Up to approximately 27 months
Part 1A: Nature and Frequency of Dose-limiting Toxicities (DLTs)
Periodo de tiempo: From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
Part 2A: Nature and Frequency of DLTs
Periodo de tiempo: From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
Parts 1A and 1B: Recommended Phase 2 Dose (RP2D) Range of RO7821657
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Part 2A: RP2D Range of RO7821657
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Parts 1 and 2: Serum Concentration of RO7821657
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Objective Response Rate (ORR)
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Disease Control Rate (DCR)
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Duration of Response (DoR)
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Progression-free Survival (PFS)
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: PFS Rate
Periodo de tiempo: At 6 months
At 6 months
Parts 1 and 2: Overall Survival (OS) Rate
Periodo de tiempo: At 6 months
At 6 months
Parts 1 and 2: Correlation of Baseline Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Tumor Expression With Clinical Activity
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Part 1B: Cluster of Differentiation 8 (CD8) Expression in Tumor Tissue
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Parts 1C and 2B: Percentage of Participants With Presence, Frequency, Severity and Interference of Symptomatic Treatment Toxicities as Assessed by NCI Patient-reported Outcomes (PRO)-CTCAE
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Parts 1C and 2B: Change From Baseline in Symptomatic Treatment Toxicities as Assessed by NCI PRO-CTCAE
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months
Parts 1C and 2B: Percentage of Participants Troubled by Treatment Symptoms, as Assessed by Single Item European Organisation for Research and Treatment of Cancer Item Library 46 (EORTC IL46)
Periodo de tiempo: Up to approximately 27 months
Up to approximately 27 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Clinical Trials, Hoffmann-La Roche

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de noviembre de 2026

Finalización primaria (Estimado)

31 de mayo de 2030

Finalización del estudio (Estimado)

31 de mayo de 2030

Fechas de registro del estudio

Enviado por primera vez

14 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de octubre de 2026

Publicado por primera vez (Actual)

20 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • BP46447
  • 2026-526150-14-00 (Ctis)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .